Cantor Fitzgerald Starts Tango Therapeutics Inc. (TNGX) at Overweight, 'A Full Dance Card of Novel Cancer Candidates'

Cantor Fitzgerald analyst Eric Schmidt initiates coverage on Tango Therapeutics Inc. (NASDAQ: TNGX) with a Overweight rating.

The analyst comments "We are initiating coverage of Tango Therapeutics with an Overweight rating. Tango is a fully-integrated, small-molecule, drug-discovery and development organization anchored on the premise of synthetic lethality for treating solid tumors. The company has four compounds in Phase 1 development, each with large commercial potential and the opportunity to be first-in-class drugs. Proof-of-concept data could be associated with meaningful stock upside given TNGX's modest valuation (enterprise value of ~ $500M)."

For an analyst ratings summary and ratings history on Tango Therapeutics Inc. click here. For more ratings news on Tango Therapeutics Inc. click here.

Shares of Tango Therapeutics Inc. closed at $7.68 yesterday.

You May Also Be Interested In

• BMO Capital Resumes Global Net Lease (GNL), Upgrades to Outperform
• H.C. Wainwright Assumes Alpha Compute Corp. (ALP) at Neutral
• BTIG Starts Freenome Inc. (FRNM) at Buy